A New Guideline for Personalizing Cancer Drug Dosing
The Clinical Pharmacogenetics Implementation Consortium (CPIC) has released an updated 2025 guideline for dosing thiopurine drugs, a class of medications used in the treatment of certain leukemias and autoimmune conditions. The guideline provides specific recommendations for adjusting the starting doses of mercaptopurine, thioguanine, and azathioprine based on a patient’s genetic profile for two key enzymes: TPMT and NUDT15. Individuals carrying genetic variants that reduce or eliminate the activity of these enzymes are at a significantly higher risk of severe, potentially life-threatening myelosuppression when given standard doses. This update underscores the critical role of pharmacogenomics in precision oncology, aiming to minimize adverse effects and improve therapeutic safety across diverse populations.
Why it might matter to you: For oncologists and clinical pharmacologists, this guideline directly addresses a key challenge in precision medicine: preventing severe toxicity from common chemotherapeutic agents. Implementing this genetic testing can refine treatment protocols, reduce hospitalizations for adverse events, and improve patient outcomes in hematologic malignancies. It represents a concrete step toward integrating genomic biomarkers into standard clinical workflows for safer, more personalized cancer care.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
